Top Content

view more
article-block

Sustainable drug delivery devices: striking a balance between aspirations and current possibilities

Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable

 17 July 2024
article-block

Exploring disease modification to change the future of epilepsy treatment

Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies

 17 July 2024
article-block

The role of AI in patient support

Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise

 17 July 2024
article-block

The infected blood scandal: a timeline

Betsy Goodfellow from Pharmafocus considers the details of the infected blood scandal, from its beginning to the outcome of the recent inquiry

 17 July 2024
article-block

Pride month and LGBTQ+ healthcare

Betsy Goodfellow from Pharmafocus considers Pride month and the state of LGBTQ+ healthcare in the UK

 4 June 2024
article-block

Epilepsy and brain health: a call for global action and unity

Rafal Kaminski from Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment

 28 April 2024

Industry Insights

view more
article-block

Sustainable drug delivery devices: striking a balance between aspirations and current possibilities

Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable

 17 July 2024
article-block

Exploring disease modification to change the future of epilepsy treatment

Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies

 17 July 2024
article-block

The role of AI in patient support

Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise

 17 July 2024
article-block

20 years of EGFR in NSCLC: how precision medicine helps navigate lung cancer challenges

Henar Hevia at Johnson & Johnson considers the progress that has been made in lung cancer treatment since the discovery of EGFR, including the evolving treatment paradigm, the role of precision medicine in treatment decision-making and quality of life for patients receiving targeted treatments

 4 June 2024
article-block

Paediatric clinical trials for obesity treatment

Alan Baldridge and Heather Peterson from ICON consider the prevalence of paediatric obesity and assess clinical trials of its treatments

 4 June 2024
article-block

Epilepsy and brain health: a call for global action and unity

Rafal Kaminski from Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment

 28 April 2024

UK News

view more
article-category

First nasal spray for treatment of anaphylaxis approved by FDA

Ars pharmaceuticals has been granted approval by the us food and drug administration (fda) for their epinephrine nasal spray, neffy, to be used as treatment of type 1 allergic reactions including anaphylaxis.

article-category

Novo Holdings invests in Oxford Nanopore Technologies

Leading life science investor novo holdings has announced a £50m investment in oxford nanopore technologies. Oxford nanopore technologies is a leading uk-listed company currently specialising in a new generation of molecular sensing technology based on nanopores.

article-category

Cresset collaborates with Enamine to enable the design of new targeted protein degraders

Drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research organisation (cro) Enamine.

article-category

First oral treatment for hormone-sensitive prostate cancer recommended by NICE

Accord healthcare have recently announced that NICE have recommended the first oral androgen deprivation therapy (adt) treatment for hormone-sensitive prostate cancer. Prostate cancer is the most common cancer in men across the uk.

article-category

Verisense announce opening of Digital Biobank

This month, Verisense have announced that their digital biobank, with data from over one million people, is open for business.

article-category

Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment

Biotechnology company Levicept has announced positive results from its phase 2 trial into levi-04 for the treatment of osteoarthritis.

article-category

Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial

Calliditas therapeutics ab has recently announced that the phase 2b transform trial met its primary endpoint. The trial showed statistically significant improvement in alkaline phosphatase (alp) for both doses tested versus placebo. the trial evaluated setanaxib, a nox enzyme inhibitor, in patients with primary biliary cholangitis (pbc) and elevated liver stiffness.

article-category

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

Merck (known as MSDoutside of the US and Canada) has announced that its anti-pd-1 therapy, in combination with padcev (enfortuman vedotin-ejfv), has received a positive opinion from the European Medicines Agency (EMA)

article-category

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young

Researchers at the UCLA Health jonsson comprehensive cancer center have announced that they are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine. The vaccine targets h3 g34-mutant diffuse hemispheric glioma, an aggressive brain tumour typically found in adolescents and young people.

article-category

The National Institute for Health and Care Excellence announce technology appraisal guidance

The National Institute for Health and Care excellence (NICE) have recommended adult patients in England or Wales with moderately or severely active ulcerative colitis (uc) who have not responded well to or cannot tolerate conventional or biological therapy including a tumour necrosis factor (tnf) alpha inhibitor the option of skyrizi (risankizumab).

article-category

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated

This month, Janssen-Cilag international, part of johnson & johnson (j&j) has announced that the European Commission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (nsclc) with an epidermal growth factor receptor (EGFR).

article-category

Eisai and EcoNaviSta enter dementia collaboration

Eisai and Econavista have announced that they have entered into a business alliance agreement, initiating their collaboration intended to build an ecosystem in the field of dementia.

article-category

AbbVie acquires Cerevel Therapeutics

AbbVie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline.

article-category

Merck to acquire Curon Biopharmaceutical’s B-cell depletion therapy

Merck (known as MSD outside the US and Canada) have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire cn201, a novel investigational clinical-stage bispecific antibody for the treatment of b-cell associated diseases.

article-category

Collaboration between global cancer center and Absci to use generative AI for therapeutics research

Memorial Sloan Kettering (MSK) have paired with Absci corporation to develop and discover new novel therapeutics through the use of generative artificial intelligence (genAI).

article-category

Dive into the heart of pharma at CPHI Milan 2024

Join us at CPHI Milan 2024, the premier global event for pharmaceutical professionals, from 8-10 October at Fiera Milano, Milan, Italy. Celebrating 35 years of excellence, this event promises unparalleled opportunities for networking, innovation and professional growth. With over 62,000 attendees and 2,500 exhibitors, you’ll experience insightful seminars, cutting-edge exhibitions and new awards such as ‘Woman of the Year’ and ‘Future Leader’.

Global News

view more
article-category

First nasal spray for treatment of anaphylaxis approved by FDA

Ars pharmaceuticals has been granted approval by the us food and drug administration (fda) for their epinephrine nasal spray, neffy, to be used as treatment of type 1 allergic reactions including anaphylaxis.

article-category

FDA approves drug for primary biliary cholangitis

Accelerated approval has been granted for Gilead science’s livdelzi (seladelpar) to treat primary biliary cholangitis (pbc) by the US Food and Drug Administration (FDA).

article-category

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

Merck (known as MSDoutside of the US and Canada) has announced that its anti-pd-1 therapy, in combination with padcev (enfortuman vedotin-ejfv), has received a positive opinion from the European Medicines Agency (EMA)

article-category

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young

Researchers at the UCLA Health jonsson comprehensive cancer center have announced that they are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine. The vaccine targets h3 g34-mutant diffuse hemispheric glioma, an aggressive brain tumour typically found in adolescents and young people.

article-category

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated

This month, Janssen-Cilag international, part of johnson & johnson (j&j) has announced that the European Commission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (nsclc) with an epidermal growth factor receptor (EGFR).

article-category

Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour

Adaptimmune therapeutics has announced that the US Food and Drug Administration (FDA) has given accelerated approval for tecelra (afamitresgene autoleucel), the first engineered cell therapy for a solid tumour cancer approved in the US.

article-category

Johnson & Johnson’s MedTech announce orthopaedics receives 501K clearance from FDA

Orthopaedics branch of Johnson and Johnson Medtech, Depuy Synthes, has announced that their surgical robotics system velys active has received 501k clearance from the US Food and Drug Administration (FDA).

article-category

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development and co-commercialisation agreement – already investigating three dxd antibody drug conjugates (adcs) ‒ to include mk-6070.

article-category

AbbVie acquires Cerevel Therapeutics

AbbVie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline.

article-category

Dive into the heart of pharma at CPHI Milan 2024

Join us at CPHI Milan 2024, the premier global event for pharmaceutical professionals, from 8-10 October at Fiera Milano, Milan, Italy. Celebrating 35 years of excellence, this event promises unparalleled opportunities for networking, innovation and professional growth. With over 62,000 attendees and 2,500 exhibitors, you’ll experience insightful seminars, cutting-edge exhibitions and new awards such as ‘Woman of the Year’ and ‘Future Leader’.

article-category

Unmet needs in primary biliary cholangitis: Understanding challenges

How is primary biliary cholangitis (PBC) currently affecting patients; and, more importantly, what hopes does PBC Awareness Month bring for new treatment options?

article-category

Eisai and Biogen’s Leqembi launched for AD in China

Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia, following its approval in January 2024.

article-category

Eli Lilly and UNICEF extend partnership for risk of non-communicable diseases in young people

Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand UNICEF's work to ‘improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India’, according to the press release.

article-category

FDA grants expanded ODD to immunotherapy created at Roswell Park Comprehensive Cancer Center

The FDA has granted an expanded orphan drug designation (ODD) for brain cancer immunotherapy survaxm, originally created at Roswell Park Comprehensive Cancer Center.

article-category

Merck’s Capvaxive approved by FDA for prevention of pneumococcal disease

Merck has announced that the FDA has approved capvaxive (pneumococcal 21-valent conjugate vaccine).

article-category

FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment

Eli Lilly has announced that the FDA has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for iv infusion) for the treatment of adult patients with early symptomatic Alzheimer’s disease (AD).

European News

view more
article-category

First nasal spray for treatment of anaphylaxis approved by FDA

Ars pharmaceuticals has been granted approval by the us food and drug administration (fda) for their epinephrine nasal spray, neffy, to be used as treatment of type 1 allergic reactions including anaphylaxis.

article-category

FDA approves drug for primary biliary cholangitis

Accelerated approval has been granted for Gilead science’s livdelzi (seladelpar) to treat primary biliary cholangitis (pbc) by the US Food and Drug Administration (FDA).

article-category

First oral treatment for hormone-sensitive prostate cancer recommended by NICE

Accord healthcare have recently announced that NICE have recommended the first oral androgen deprivation therapy (adt) treatment for hormone-sensitive prostate cancer. Prostate cancer is the most common cancer in men across the uk.

article-category

Verisense announce opening of Digital Biobank

This month, Verisense have announced that their digital biobank, with data from over one million people, is open for business.

article-category

Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment

Biotechnology company Levicept has announced positive results from its phase 2 trial into levi-04 for the treatment of osteoarthritis.

article-category

Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial

Calliditas therapeutics ab has recently announced that the phase 2b transform trial met its primary endpoint. The trial showed statistically significant improvement in alkaline phosphatase (alp) for both doses tested versus placebo. the trial evaluated setanaxib, a nox enzyme inhibitor, in patients with primary biliary cholangitis (pbc) and elevated liver stiffness.

article-category

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

Merck (known as MSDoutside of the US and Canada) has announced that its anti-pd-1 therapy, in combination with padcev (enfortuman vedotin-ejfv), has received a positive opinion from the European Medicines Agency (EMA)

article-category

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young

Researchers at the UCLA Health jonsson comprehensive cancer center have announced that they are launching a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine. The vaccine targets h3 g34-mutant diffuse hemispheric glioma, an aggressive brain tumour typically found in adolescents and young people.

article-category

The National Institute for Health and Care Excellence announce technology appraisal guidance

The National Institute for Health and Care excellence (NICE) have recommended adult patients in England or Wales with moderately or severely active ulcerative colitis (uc) who have not responded well to or cannot tolerate conventional or biological therapy including a tumour necrosis factor (tnf) alpha inhibitor the option of skyrizi (risankizumab).

article-category

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated

This month, Janssen-Cilag international, part of johnson & johnson (j&j) has announced that the European Commission (EC) has approved a combined treatment of rybrevant (amivantamab) and chemotherapy (carboplatin and pemerexed) for the treatment of non-small cell lung cancer (nsclc) with an epidermal growth factor receptor (EGFR).

article-category

Adaptimmune receives US FDA Accelerated Approval for engineered cell therapy for a solid tumour

Adaptimmune therapeutics has announced that the US Food and Drug Administration (FDA) has given accelerated approval for tecelra (afamitresgene autoleucel), the first engineered cell therapy for a solid tumour cancer approved in the US.

article-category

Eisai and EcoNaviSta enter dementia collaboration

Eisai and Econavista have announced that they have entered into a business alliance agreement, initiating their collaboration intended to build an ecosystem in the field of dementia.

article-category

Johnson & Johnson’s MedTech announce orthopaedics receives 501K clearance from FDA

Orthopaedics branch of Johnson and Johnson Medtech, Depuy Synthes, has announced that their surgical robotics system velys active has received 501k clearance from the US Food and Drug Administration (FDA).

article-category

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development and co-commercialisation agreement – already investigating three dxd antibody drug conjugates (adcs) ‒ to include mk-6070.

article-category

AbbVie acquires Cerevel Therapeutics

AbbVie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline.

article-category

Merck to acquire Curon Biopharmaceutical’s B-cell depletion therapy

Merck (known as MSD outside the US and Canada) have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire cn201, a novel investigational clinical-stage bispecific antibody for the treatment of b-cell associated diseases.

How to Install

Appointments

view more
article-category

Curve Therapeutics bolsters its leadership team with appointment of Simon Jones

With his 20 years of expertise and proven track record in biotech and pharmaceutical industries, Curve Therapeutics appoints Simon Jones as chief financial officer and chief operating officer.

article-category

Adam Rosenberg replaces Dr Carlo Incerti as new chair of the board at VectorY Therapeutics

Vectory Therapeutics has announced the appointment of Adam Rosenberg as chair of the board, replacin Dr Carlo Incerti.

article-category

Dr Jonathan Appleby appointed by Mogrify as chief scientific officer

Mogrify has announced the appointment of Dr Jonathan Appleby as chief scientific officer.

article-category

Professor yih-shing duh appointed as chief scientific advisor by H.E.L. Group

Professor Yih-Shing Duh appointed as chief scientific advisor by H.E.L. Group

article-category

Enhanc3D Genomics appoints Hazel Jones as CEO

Enhanc3D Genomics has announced the appointment of Hazel Jones as chief executive officer (CEO), following a successful six-month term as interim CEO and COO.

article-category

Closed Loop Medicine appoints Paul Johnson as non-executive director

Closed loop medicine has announced the appointment of Paul Johnson as an independent non-executive director.

article-category

Sphere Fluidics appoints Curtis Nicholson as director of sales EMEA

Sphere Fluidics has announced the appointment of Curtis Nicholson as director for sales for Europe, Middle East and Africa (EMEA).

article-category

Dr Alison Evans appointed head of education and training at Drug Safety Research Unit

Drug Safety Research Unit appoints Dr Alison Evans as head of education and training.

article-category

Margrethe Sørgaard appointed SVP clinical operations and pharmacovigilance at Calluna Pharma

Calluna Pharma has announced that it has appointed Margrethe Sørgaard as senior vice president of clinical operations and pharmacovigilance.

article-category

Jaap Stuut appointed as president and general manager of Sakura Finetek Europe

Sakura Finetek Europe has announced the appointment of Jaap Stuut as president and general manager, effective immediately.

article-category

Meenu Chhabra Karson appointed board chair of Harness Therapeutics

Harness Therapeutics has announced the appointment of Meenu Chhabra Karson as chair of its board of directors.

article-category

Bob Kain joins Single Technologies as advisor

Single Technologies has announced that it has appointed Bob Kain as an advisor to support the commercialisation of its 3D sequencing system.

article-category

Joseph Bertelsen appointed CCO of Nuclera

Nuclera has announced that it has appointed Joseph Bertelsen as chief commercial officer (CCO).

article-category

Dr James Malone appointed CTO at BenevolentAI

BenevolentAI has announced that Dr Daniel Neil, current chief technology officer (CTO) is stepping down, to be succeeded by Dr James Malone, who joins the company in April.

article-category

Vynamic appoints new head of life sciences Europe

Vynamic has announced the appointment of Gemma Pfister as head of life sciences Europe.

article-category

Parexel announces new CEO

Parexel has announced that its CEO, Jamie MacDonald will retire, with the company’s current chief operating and growth officer Peyton Howell taking over as CEO, effective 15 May 2024.